Publications: LoDoCo2

• Time to commence or time out for colchicine in secondary prevention of cardiovascular disease?Eur Heart J - LoDoCo2 - ASCVD April 2021
• Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trialsEuropean Heart Journal - Fiolet, A.; Mosterd, dr. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD February 2021
• Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic SubstudyCirculation - Abstract - Fiolet, A.; The, dr. S.H.K.; Mosterd, dr. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD August 2020
• Colchicine in Patients with Chronic Coronary DiseaseNew England Journal of Medicine - Abstract - Mosterd, dr. A.; Fiolet, A.; The, dr. S.H.K.; Lenderink, dr. T.; Hoogslag, drs. P.A.M.; Jerzewski, dr. A.; Nierop, drs. P.R.; Swart, drs. H.P.; Schaap, dr. J.; Kuijper, dr. A.F.M.; Hessen, dr. M.W.J. van; Dirksen, dr. M.T.; Alings, prof. dr. A.M.W.; Schut, drs. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD August 2020
• Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C- reactive proteinPLoS One - Abstract - Fiolet, A.; Mosterd, dr. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD August 2020
• The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.Am Heart J - Abstract - Fiolet, A.; Schut, drs. A.; Mosterd, dr. A.; Cornel, prof. dr. J.H. - LoDoCo2 - ASCVD October 2019